Michael Spinner, MD, BA

Clinical Assistant Professor

I am a hematologist/oncologist and care for patients with blood cancers with a particular focus on Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and Waldenstrom macroglobulinemia. I have a particular interest in immunotherapy, targeted therapies, stem cell transplantation, and CAR T-cell therapy, in which a patient’s T cells are engineered to target and kill cancer cells.

My research focuses on novel immunotherapy approaches to treat lymphoma and personalized medicine, tailoring treatment to individual patients based on their disease characteristics and tumor genetics. I am a co-investigator on clinical trials evaluating new immunotherapies to treat lymphoma and collaborate with leading scientists on identifying biomarkers to predict which patients may benefit from certain treatments.

I received my medical degree from Vanderbilt University and completed my internal medicine residency and hematology/oncology fellowship from Stanford University under the mentorship of Dr. Ranjana Advani. I serve on the Hodgkin lymphoma guidelines committee for the National Comprehensive Cancer Network.

Education
06/2020 - Hematology/Oncology, Stanford University Medical Center
06/2016 - Internal Medicine, Stanford University Medical Center
MD, 05/2014 - Medicine, Vanderbilt University School of Medicine
BA, 05/2009 - Music (Classical Guitar), Emory University
Honors and Awards
  • Young Investigator Award, Conquer Cancer Foundation, 2020
  • Scientific Merit Award, Stanford Hematology/Oncology Fellowship Program, 2020
  • ASH Clinical Research Training Institute, American Society of Hematology, 2018
  • ASH Abstract Achievement Award, American Society of Hematology, 2016
  • NIAID Merit Award, National Institute of Allergy and Infectious Diseases, 2014
  • Julian Wolfsohn Award for Outstanding Performance in Internal Medicine, Stanford Internal Medicine Residency Program, 2014
  • Stanford Society of Physician Scholars, Stanford University School of Medicine, 2014
  • Alpha Omega Alpha, Vanderbilt University School of Medicine, 2014
  • Rudolph H. Kampmeier Prize in Clinical Medicine, Vanderbilt University School of Medicine, 2014
  • NIH Medical Research Scholars Program, National Institutes of Health, 2012
  • Phi Beta Kappa, Emory University, 2008
  • William H. Murdy Natural Science and Mathematics Award, Emory University, 2007
Publications

  1. Spinner MA, Advani RH. Emerging immunotherapies in the Hodgkin Lymphoma Armamentarium. Expert opinion on emerging drugs 2024. PMID: 38676917


  2. Abrams H, Abuali I, Khan AM, Riano I, Allen G, Spinner MA, Komanduri KV. Cell Therapy: Actionable Takeaways from the 2023 Precision Oncology Summit Session Current Trauma Reports 2024. PMID:


  3. Khanna V, Lu R, Kumar J, Molina A, Stehr H, Spiteri E, Spinner M, Silva O, Fernandez-Pol S, Tan B, Greenberg PL. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms. Leukemia research 2023. PMID: 38154193


  4. Desai SH, Spinner MA, Evens AM, Sýkorová A, Bachanova V, Goyal G, Kahl BS, Dorritie KA, Azzi J, Kenkre VP, Chang C, Michalka J, Ansell SM, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah HR, Wagner-Johnston ND, Arai S, Nowakowski GS, Mocikova H, Jagadeesh D, Blum K, Diefenbach C, Iyengar S, Rappazzo KC, Baidoun F, Choi Y, Prochazka V, Advani RH, Micallef IN. Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. Blood advances 2023. PMID: 37729621


  5. Spinner MA, Komanduri KV. Long-term Survivors and Failures of CAR-T Therapy for Lymphoma: Is there a Role for Allogeneic Transplantation After the CAR-T Crash? Transplantation and cellular therapy 2023. PMID: 38035887


  6. Bowers JT, Anna JL, Bair SM, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen JDK, Ayers EC, Wagner C, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood advances 2023. PMID: 37595053


  7. Randall MP, Spinner MA. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. Cancers 2023. PMID: 37760478


  8. Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB. Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy. European journal of nuclear medicine and molecular imaging 2023. PMID: 37300573


  9. Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, Frank MJ, Johnston LJ, Miklos DB, Muffly L, Negrin RS, Rezvani AR, Shiraz P, Shizuru JA, Weng WK, Binkley MS, Hoppe RT, Advani RH, Arai S. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood 2023. PMID: 36857637


  10. Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Volume 98 of Issue 3. American journal of hematology 2023. PMID: 36629030


  11. Spinner MA, Advani RH. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. Volume 36 of Issue 1. Oncology (Williston Park, N.Y.) 2022. PMID: 35089671


  12. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Volume 139 of Issue 3. Blood 2022. PMID: 34570876


  13. Brar N, Spinner MA, Baker MC, Advani RH, Natkunam Y, Lewis DB, Silva O. Increased double-negative a�+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease. Volume 107 of Issue 1. Haematologica 2022. PMID: 34474549


  14. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R. Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Volume 22 of Issue 7. Clinical lymphoma, myeloma & leukemia 2021. PMID: 35093285


  15. Dworkin ML, Jiang AL, Von Eyben R, Spinner MA, Advani RH, Lowsky R, Hiniker SM, Hoppe RT. Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant. Volume 57 of Issue 1. Bone marrow transplantation 2021. PMID: 34671121


  16. Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, Federico M. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Volume 138 of Issue 3. Blood 2021. PMID: 34292324


  17. Marciano BE, Olivier KN, Folio LR, Zerbe CS, Hsu AP, Freeman AF, Filie AC, Spinner MA, Sanchez LA, Lovell JP, Parta M, Cuellar-Rodriguez JM, Hickstein DD, Holland SM. Pulmonary Manifestations of GATA2 Deficiency. Volume 160 of Issue 4. Chest 2021. PMID: 34089740


  18. Menke JR, Spinner MA, Natkunam Y, Warnke RA, Advani RH, Gratzinger DA. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. Volume 145 of Issue 6. Archives of pathology & laboratory medicine 2021. PMID: 32991677


  19. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Volume 5 of Issue 6. Blood advances 2021. PMID: 33710337


  20. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Volume 35 of Issue 9. Leukemia 2021. PMID: 33658659


  21. Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, Yeung J, Spinner MA, Lunning M, Inghirami G, Moskowitz A, Galasso N, Ganesan N, van der Weyden C, Ruan J, Prince HM, Trotman J, Advani R, Dogan A, Horwitz S. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Volume 4 of Issue 19. Blood advances 2020. PMID: 33002132


  22. Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera A, Chen R, Tomassetti S, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta S, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Volume 25 of Issue 10. The oncologist 2020. PMID: 32720734


  23. Spinner MA, Aleshin A, Santaguida MT, Schaffert SA, Zehnder JL, Patterson AS, Gekas C, Heiser D, Greenberg PL. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms. Volume 4 of Issue 12. Blood advances 2020. PMID: 32569379


  24. Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Volume 191 of Issue 1. British journal of haematology 2020. PMID: 32430944


  25. Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Volume 25 of Issue 6. The oncologist 2020. PMID: 32275786


  26. Spinner MA, Kennedy VE, Tamaresis JS, Lavori PW, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Rezvani AR, Shizuru JA, Weng WK, Hoppe RT, Strober S, Lowsky R. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Volume 3 of Issue 16. Blood advances 2019. PMID: 31427277


  27. Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Volume 37 of Issue 24. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019. PMID: 31157579


  28. Spinner MA, Advani RH. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Volume 2018 of Issue 1. Hematology. American Society of Hematology. Education Program 2018. PMID: 30504311


  29. Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Volume 184 of Issue 1. British journal of haematology 2018. PMID: 30485408


  30. Spinner MA, Varma G, Advani RH. Novel Approaches in Waldenstr�m Macroglobulinemia. Volume 32 of Issue 5. Hematology/oncology clinics of North America 2018. PMID: 30190025


  31. Spinner MA, Advani RH, Hoppe RT, Lowsky R, Muffly LS. Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Volume 2 of Issue 13. Blood advances 2018. PMID: 29970391


  32. Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C. New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Volume 38. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018. PMID: 30231319


  33. Spinner MA, Fern?ndez-Vi?a M, Creary LE, Quinn O, Elder L, Arai S, Johnston LJ, Meyer EH, Miklos DB, Muffly LS, Negrin RS, Shizuru JA, Weng WK, Laport GG, Strober S, Lowsky R, Rezvani AR. HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Volume 1 of Issue 17. Blood advances 2017. PMID: 29296777


  34. Spinner MA, Ker JP, Stoudenmire CJ, Fadare O, Mace EM, Orange JS, Hsu AP, Holland SM. GATA2 deficiency underlying severe�blastomycosis and fatal herpes simplex virus-associated hemophagocytic lymphohistiocytosis. Volume 137 of Issue 2. The Journal of allergy and clinical immunology 2015. PMID: 26395816


  35. Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Volume 123 of Issue 6. Blood 2013. PMID: 24227816


  36. Shah SK, Hull SC, Spinner MA, Berkman BE, Sanchez LA, Abdul-Karim R, Hsu AP, Claypool R, Holland SM. What does the duty to warn require? Volume 13 of Issue 10. The American journal of bioethics : AJOB 2013. PMID: 24024817


  37. Spinner MA, Paulin HN, Wester CW. Duodenal histoplasmosis presenting with upper gastrointestinal bleeding in an AIDS patient. Volume 2012. Case reports in gastrointestinal medicine 2012. PMID: 23091745